In short
Clinical trials are investigating Azd8205 in people with advanced or metastatic solid cancers, including B7-H4-selected endometrial cancer. These studies aim to assess safety, tolerability, and how well Azd8205 works, including the best dose and survival outcomes.
Key points
- Clinical trials of Azd8205 are studying people with advanced or metastatic cancers. One completed Phase I/IIa study looked at Azd8205 alone and with other anticancer drugs in solid tumors, mainly to assess safety, tolerability, and dose. A Phase III study is now authorised for B7-H4-selected endometrial cancer after prior platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy. That later trial compares Azd8205 with physician’s choice chemotherapy. The main outcomes are progression-free survival and overall survival.
Clinical trials overview
The available trial data show two studies of Azd8205 in cancer patients. One is a completed early study in advanced or metastatic solid malignancies, and the other is an authorised Phase III study in B7-H4-selected advanced or metastatic endometrial cancer.
These trials are not general medicine studies. They are focused on specific cancer groups and are designed to test safety, dose, and treatment benefit.
Phase I/IIa study in advanced solid malignancies
The first study was a Phase I/IIa interventional trial and is now completed. It enrolled 183 participants with advanced or metastatic solid cancers.
This study looked at Azd8205 as monotherapy, which means treatment with Azd8205 alone, and also in combination with other anticancer drugs. The brief summary says the main goals were to assess safety and tolerability and to find the maximum tolerated dose and/or the recommended Phase 2 dose.
These goals are typical for an early cancer trial. In simple terms, the researchers wanted to learn how much treatment could be given safely and what dose should be studied next.
Phase III study in endometrial cancer
The second study is a global Phase III trial and is authorised. It studies Puxitatug Samrotecan (Azd8205) as monotherapy compared with physician’s choice of chemotherapy in B7-H4-selected endometrial cancer that progressed after platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy.
The trial plans to enroll 701 participants. The chemotherapy choices listed in the source are paclitaxel and doxorubicin.
This study is later-stage research, so it is mainly designed to compare outcomes between treatment groups. It is not focused on dose-finding, but on whether Azd8205 can improve important cancer outcomes compared with standard chemotherapy.
Who can participate
The completed Phase I/IIa study included participants with advanced or metastatic solid malignancies. That means people had cancers that were advanced, had spread, or both.
The Phase III study is narrower and is for people with B7-H4-selected advanced/metastatic endometrial cancer. The cancer must also have progressed after platinum-based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
“Selected” means the trial uses a specific cancer marker, B7-H4, to choose the study group. This helps researchers study Azd8205 in a more defined patient population.
What the trials measure
In the Phase I/IIa study, the main focus was safety, tolerability, the maximum tolerated dose, and the recommended Phase 2 dose. Safety means whether the treatment can be given without causing unacceptable harm. Tolerability means how well people can handle the treatment.
In the Phase III study, the main outcomes are progression-free survival and overall survival. Progression-free survival is the time until the cancer gets worse or the person dies. Overall survival is the time until death from any cause.
The Phase III trial defines progression by RECIST 1.1 and uses BICR, which means blinded independent central review. In simple words, this is a careful and unbiased way to check whether the cancer has grown.
Key patient terms
Interventional trial means the researchers give a treatment and then measure the results.
Monotherapy means one treatment only, while combination therapy means more than one treatment together.
Physician’s choice of chemotherapy means the doctor chooses from the study’s listed standard chemotherapy options.
Endometrial cancer is cancer that starts in the lining of the uterus.